Digital health funding rebounds with megadeals, but the money is concentrating at the top
Rock Health says digital health startups raised $4 billion in Q1, driven by 12 megadeals, while other reporting points to a broader $1 billion boost since Q1 2025. The headline is recovery, but the more important story is concentration: capital is flowing to a smaller number of companies that already look like category leaders.
After a long period of investor caution, the digital health funding market is showing signs of life again. Yet this is not a broad-based rebound. The data points to a market in which confidence is returning selectively, with megadeals doing most of the heavy lifting while smaller startups continue to struggle for attention.
That matters because digital health has spent years trying to prove it can mature beyond a high-volume startup ecosystem into a durable industry. A funding environment dominated by large rounds rewards companies with clearer distribution, stronger reimbursement pathways, and more credible operating models. In other words, investors are favoring evidence over experimentation.
The flip side is that the middle of the market may be hollowing out. If capital keeps concentrating in fewer firms, then early-stage innovation could become harder to finance, and many promising companies may never reach the scale needed to validate their products. That could narrow the pipeline of future platform companies even as the sector’s headline numbers improve.
For healthcare buyers, the shift may be welcome. Fewer, better-capitalized vendors can mean more stability and less churn. But for the broader ecosystem, this looks like a discipline phase: the market is still interested in digital health, just much less interested in vague promises.